Insulin, glucose and the increased risk of cancer in patients with type 2 diabetes

Diabetologia

Volumn 53, Issue 10, 2010, Pages 2086-2088

  Johnson, J A ^b   Pollak, M ^a  

^a MCGILL UNIVERSITY   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GLITAZONE DERIVATIVE; GLUCOSE; INSULIN; INSULIN DERIVATIVE; METFORMIN; SULFONYLUREA DERIVATIVE;

CANCER GROWTH; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CLINICAL TRIAL; DIET THERAPY; EPIDEMIOLOGICAL DATA; GLUCOSE BLOOD LEVEL; GLYCOLYSIS; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN RESISTANCE; MALIGNANT NEOPLASTIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PRIORITY JOURNAL;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; NEOPLASMS; RISK;

EID: 77958028525     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-010-1855-0     Document Type: Note

References (32)

1. Evans JMM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD (2005) Metformin and reduced risk of cancer in diabetic patients. BMJ 330:1304-1305
2. Currie CJ, Poole CD, Gale EA (2009) The influence of glucose- lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52:1766-1777
3. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM (2009) New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 32:1620-1625
4. Bowker SL, Yasui Y, Veugelers P, Johnson JA (2010) Glucoselowering therapies and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure. Diabetologia 53:1631-1637
5. Govindarajan R, Ratnasinghe L, Simmons DL et al (2007) Thiazolidinediones and risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol 25:1476-1481
6. Yang YX, Hennessy S, Lewis JD (2004) Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology 127:1044-1050
7. Bowker SL, Majumdar SR, Veugelers P, Johnson JA (2006) Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29:254-258
8. Hemkens LG, Grouven U, Bender R et al (2009) Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 52:1732-1744
9. Mannucci E, Monami M, Balzi D et al (2010) Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care. doi:10.2337/dc10-0476
10. Pollak M (2009) Do cancer cells care if their host is hungry? Cell Metab 9:401-103
11. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M (2006) Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 66:10269-10273
12. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N (2007) Metformin inhibits mammalian target of rapamycindependent translation initiation in breast cancer cells. Cancer Res 67:10804-10812
13. Burton JD, Goldenberg DM, Blumenthal RD (2008) Potential of peroxisome proliferator-activated receptor gamma antagonist compounds as therapeutic agents for a wide range of cancer types. PPAR Res 2008:494161
14. Tachibana K, Yamasaki D, Ishimoto K, Doi T (2008) The role of PPARs in cancer. PPAR Res 2008:102737
15. Gerstein HC (2010) Does insulin therapy promote, reduce, or have a neutral effect on cancers? JAMA 303:446-447
16. Pollak M (2008) Insulin and insulin-like growth factor signaling in neoplasia. Nat Rev Cancer 8:915-928
17. Tannock IF, Kopelyan I (1986) Influence of glucose concentration on growth and formation of necrosis in spheroids derived from a human bladder cancer cell line. Cancer Res 46:3105-3110
18. Frasca F, Pandini G SP et al (1999) Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol 19:3278-3288
19. Vella V, Pandini G, Sciacca L et al (2002) A novel autocrine loop involving IGF-II and the insulin receptor isoform-A stimulates growth of thyroid cancer. J Clin Endocrinol Met 87:245-254
20. Heuson JC, Legros N (1972) Influence of insulin deprivation on growth of the 7, 12 dimethylbenz(a) anthracene-induced mammary carcinoma in rats subjected to alloxan diabetes and food restriction. Cancer Res 32:226-232
21. Algire C, Amrein L, Zakikhani M, Panasci L, Pollak M (2010) Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase. Endocr Relat Cancer 17:351-360
22. Yang X, Ko GT, So WY et al (2010) Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong Diabetes Registry. Diabetes 59:1254-1260
23. Johnson JA, Gale EA (2010) Diabetes, insulin use, and cancer risk: are observational studies part of the solution-or part of the problem? Diabetes 59:1129-1131
24. Carstensen B (2010) Comment on Yang et al.: Associations of hyperglycaemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong Diabetes Registry. Diabetes 2010, in press
25. Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM (2005) Fasting serum glucose level and cancer risk in Korean men and women. JAMA 293:194-202
26. Park SM, Lim MK, Shin SA, Yun YH (2006) Impact of prediagnosis smoking, alcohol, obesity, and insulin resistance on survival in male cancer patients: National Health Insurance Corporation Study. J Clin Oncol 24:5017-5024
27. Schoen RE, Tangen CM, Kuller LH et al (1999) Increased blood glucose and insulin, body size, and incident colorectal cancer. J Natl Cancer Inst 91:1147-1154
28. Kaaks R, Toniolo P, Akhmedkhanov A et al (2000) Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst 92:1592-1600
29. Ma J, Giovannucci E, Pollak M et al (2004) A prospective study of plasma C-peptide and colorectal cancer risk in men. J Natl Cancer Inst 96:546-553 (Pubitemid 38559579)
30. UK Prospective Diabetes Group (1998) Effect of intensive bloodglucose control with metformin on complications in overweight patients with type 2 diabetes. UKPDS 34. Lancet 352:854-865
31. UK Prospective Diabetes Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. UKPDS 33. Lancet 352:837-853
32. Turner RC, Cull CA, Frighi V, Holman RR (1999) Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 281:2005-2012